NovoCure (NVCR)

NovoCure on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.

Download CSV

12.8M

Short interest

settlement 2026-10-15

7.7

Days to cover

-2.3 days vs prior

39.0%

Short share of volume

2026-11-02

111

Fails to deliver

settlement 2026-10-13

Mon 11 Jan

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in NVCR is 12,823,054 shares, up 1,026,629 shares over the last month. Over the last 48 readings it ranged from 4,640,412 shares (30 May 2025) to 12,823,054 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 1.7M shares a day that is 7.7 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/nvcr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	12,823,054	+14.9%	1,663,731	7.71
2026-09-30	11,163,094	-5.4%	1,110,466	10.05
2026-09-15	11,796,425	+9.3%	1,027,830	11.48
2026-08-31	10,788,851	+17.6%	1,414,077	7.63
2026-08-14	9,170,033	-9.5%	1,096,067	8.37
2026-07-31	10,137,546	-11.5%	2,072,352	4.89
2026-07-15	11,460,044	-3.6%	1,530,548	7.49
2026-06-30	11,884,203	+23.1%	1,924,097	6.18
2026-06-15	9,650,837	+5.4%	1,615,169	5.98
2026-05-29	9,153,119	+7.2%	1,323,014	6.92
2026-05-15	8,541,120	+22.6%	1,993,657	4.28
2026-04-30	6,967,267	-20.0%	1,710,207	4.07
2026-04-15	8,707,784	-3.8%	1,056,187	8.24
2026-03-31	9,055,343	+6.3%	1,280,009	7.07
2026-03-13	8,518,264	-6.7%	1,410,560	6.04
2026-02-27	9,127,904	+2.6%	2,568,676	3.55
2026-02-13	8,899,112	+11.7%	3,671,454	2.42
2026-01-30	7,970,704	+7.2%	1,036,048	7.69
2026-01-15	7,432,511	-10.8%	1,330,310	5.59
2025-12-31	8,333,839	+20.0%	1,066,364	7.82
2025-12-15	6,943,501	+1.7%	2,261,775	3.07
2025-11-28	6,827,285	+14.3%	1,460,342	4.68
2025-11-14	5,971,436	+4.5%	1,874,788	3.19
2025-10-31	5,711,586	+8.9%	1,237,627	4.61
2025-10-15	5,242,339	-8.8%	2,036,264	2.57
2025-09-30	5,745,021	-2.4%	1,566,459	3.67
2025-09-15	5,886,314	-1.3%	1,480,004	3.98
2025-08-29	5,965,015	+8.3%	1,220,993	4.89
2025-08-15	5,510,180	+5.5%	1,875,967	2.94
2025-07-31	5,224,090	+6.0%	2,289,409	2.28
2025-07-15	4,927,495	-5.8%	931,636	5.29
2025-06-30	5,228,810	+5.7%	1,598,179	3.27
2025-06-13	4,944,866	+6.6%	2,104,809	2.35
2025-05-30	4,640,412	-14.0%	990,261	4.69
2025-05-15	5,395,999	-0.9%	874,634	6.17
2025-04-30	5,443,133	+6.0%	970,911	5.61
2025-04-15	5,136,017	-5.2%	778,393	6.60
2025-03-31	5,418,621	+0.4%	657,938	8.24
2025-03-14	5,399,415	+3.5%	1,055,615	5.11
2025-02-28	5,216,483	+0.3%	1,213,080	4.30
2025-02-14	5,200,063	+4.6%	767,914	6.77
2025-01-31	4,971,800	+2.0%	748,244	6.64
2025-01-15	4,874,208	-9.7%	1,113,945	4.38
2024-12-31	5,396,504	+3.9%	970,353	5.56
2024-12-13	5,192,908	-7.8%	2,709,569	1.92
2024-11-29	5,633,356	-0.6%	785,591	7.17
2024-11-15	5,669,287	-4.8%	889,394	6.37
2024-10-31	5,956,142	+3.1%	1,558,211	3.82

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of NVCR volume is 39.0%, down 13.9 points over the last five sessions. Over the last 30 readings it ranged from 30.2% (22 September 2026) to 76.8% (6 October 2026). The latest reading is 16.8 points below the 30-session average of 55.8%, on 562K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	219K	562K	39.0%	12
2026-10-30	362K	756K	47.9%	3,422
2026-10-29	958K	2.3M	42.5%	40,590
2026-10-28	526K	794K	66.3%	864
2026-10-27	210K	452K	46.4%	64
2026-10-26	219K	414K	52.9%	2
2026-10-23	207K	365K	56.8%	70
2026-10-22	229K	362K	63.4%	1,130
2026-10-21	912K	1.2M	75.2%	0
2026-10-20	428K	744K	57.6%	69
2026-10-19	316K	563K	56.2%	3,986
2026-10-16	373K	521K	71.6%	35
2026-10-15	230K	339K	67.7%	7
2026-10-14	341K	505K	67.5%	27
2026-10-13	167K	270K	61.6%	62
2026-10-12	163K	264K	61.9%	33
2026-10-09	284K	445K	63.7%	386
2026-10-08	535K	766K	69.9%	213
2026-10-07	477K	707K	67.5%	4
2026-10-06	491K	639K	76.8%	510
2026-10-05	252K	598K	42.1%	0
2026-10-02	304K	643K	47.3%	5,643
2026-10-01	222K	404K	54.9%	100
2026-09-30	230K	399K	57.5%	1,481
2026-09-29	95K	244K	39.2%	1,901
2026-09-28	127K	322K	39.5%	55
2026-09-25	156K	439K	35.5%	1
2026-09-24	252K	487K	51.7%	300
2026-09-23	173K	266K	64.8%	0
2026-09-22	138K	457K	30.2%	49

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 13 October 2026, the fails-to-deliver balance in NVCR is 111 shares, up 11 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (10 June 2026) to 52,177 shares (4 August 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-10-13	111	$14.72	$2K
2026-10-09	100	$14.22	$1K
2026-09-11	12,072	$15.35	$185K
2026-08-31	1,422	$17.82	$25K
2026-08-27	22,282	$17.89	$399K
2026-08-24	1,376	$17.10	$24K
2026-08-11	366	$17.31	$6K
2026-08-04	52,177	$15.32	$799K
2026-07-16	279	$16.03	$4K
2026-07-15	443	$15.55	$7K
2026-06-15	161	$17.78	$3K
2026-06-10	2	$17.24	$34
2026-05-26	29,728	$17.96	$534K
2026-05-18	950	$17.58	$17K
2026-05-12	488	$18.10	$9K
2026-05-08	468	$16.83	$8K
2026-05-04	743	$16.62	$12K
2026-04-30	15	$11.93	$179
2026-04-28	473	$12.48	$6K
2026-04-27	153	$12.47	$2K
2026-04-23	414	$13.02	$5K
2026-04-22	484	$12.23	$6K
2026-04-21	18,366	$12.67	$233K
2026-04-20	8,133	$12.83	$104K
2026-04-17	455	$12.62	$6K
2026-04-16	187	$12.17	$2K
2026-04-07	108	$10.55	$1K
2026-04-06	257	$10.55	$3K
2026-02-25	1,605	$11.74	$19K
2026-02-20	1,775	$11.39	$20K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for NVCR in the last 90 days. The most recent filings are listed below. Latest filing: Puri Michal Nath (Chief Human Resources Officer) on 2026-06-30.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-06-30	Puri Michal Nath	Chief Human Resources Officer	Grant	2K	$11.15	$21K	203K
2026-06-30	Leonard Frank X	Chief Executive Officer	Grant	2K	$11.15	$21K	461K
2026-06-30	Danziger Asaf	Director	Grant	268	$11.15	$3K	417K
2026-06-30	Ben Arye Barak	General Counsel	Grant	1K	$11.15	$14K	244K
2026-06-04	Leonard Frank X	Chief Executive Officer	Sell	34K	$17.93	$615K	460K
2026-06-03	Stafford Kristin	Director	Grant	12K	$0.00	$0	23K
2026-06-03	Ocean Allyson J	Director	Grant	12K	$0.00	$0	23K
2026-06-03	Scannell Timothy J	Director	Grant	12K	$0.00	$0	26K
2026-06-03	VERNON W ANTHONY	Director	Grant	12K	$0.00	$0	209K
2026-06-03	Madden Martin J.	Director	Grant	12K	$0.00	$0	30K
2026-06-03	LEUNG GABRIEL	Director	Grant	12K	$0.00	$0	101K
2026-06-03	Hung David	Director	Grant	12K	$0.00	$0	32K
2026-06-03	HILLEMAN JERYL L	Director	Grant	12K	$0.00	$0	25K
2026-06-02	Stafford Kristin	Director	Sell	3K	$15.77	$46K	11K
2026-06-02	Ocean Allyson J	Director	Sell	3K	$15.77	$46K	11K
2026-06-02	Scannell Timothy J	Director	Sell	3K	$15.77	$46K	14K
2026-06-02	VERNON W ANTHONY	Director	Sell	3K	$15.77	$46K	198K
2026-06-02	LEUNG GABRIEL	Director	Sell	3K	$15.77	$46K	89K
2026-06-02	Hung David	Director	Sell	3K	$15.77	$46K	20K
2026-06-02	HILLEMAN JERYL L	Director	Sell	3K	$15.77	$46K	14K
2026-04-28	VERNON W ANTHONY	Director	Exercise or conversion	22K	$11.39	$245K	201K
2026-03-05	Paravasthu Mukund	Chief Operating Officer	Sell	43K	$13.77	$596K	73K
2026-03-04	Paravasthu Mukund	Chief Operating Officer	Sell	5K	$13.31	$72K	116K
2026-03-04	Puri Michal Nath	Chief Human Resources Officer	Sell	1K	$13.31	$15K	201K
2026-03-04	Weinberg Uri	Chf Medical and Innovation Ofr	Sell	6K	$13.31	$85K	267K
2026-03-04	Leupin Nicolas	Former Chief Medical Officer	Sell	1K	$13.31	$15K	103K
2026-03-04	Leonard Frank X	Chief Executive Officer	Sell	6K	$13.31	$75K	494K
2026-03-04	Cordova Ashley	Former Chief Executive Officer	Tax withholding	18K	$13.30	$235K	423K
2026-03-04	Brackmann Christoph	Chief Financial Officer	Sell	6K	$13.31	$85K	183K
2026-03-03	Paravasthu Mukund	Chief Operating Officer	Grant	45K	$0.00	$0	121K
2026-03-03	Puri Michal Nath	Chief Human Resources Officer	Grant	40K	$0.00	$0	202K
2026-03-03	Weinberg Uri	Chf Medical and Innovation Ofr	Grant	50K	$0.00	$0	274K
2026-03-03	Leonard Frank X	Chief Executive Officer	Grant	150K	$0.00	$0	499K
2026-03-03	DOYLE WILLIAM F	Executive Chairman	Sell	21K	$13.43	$286K	328K
2026-03-03	DOYLE WILLIAM F	Executive Chairman	Sell	51K	$12.79	$646K	350K
2026-03-03	DOYLE WILLIAM F	Executive Chairman	Grant	200K	$0.00	$0	400K
2026-03-03	DOYLE WILLIAM F	Executive Chairman	Grant	200K	$0.00	$0	200K
2026-03-03	Brackmann Christoph	Chief Financial Officer	Grant	55K	$0.00	$0	189K
2026-03-03	Ben Arye Barak	General Counsel	Grant	50K	$0.00	$0	242K
2026-03-02	Paravasthu Mukund	Chief Operating Officer	Sell	408	$13.49	$6K	76K
2026-03-02	Weinberg Uri	Chf Medical and Innovation Ofr	Sell	3K	$13.33	$44K	223K
2026-03-02	Leonard Frank X	Chief Executive Officer	Sell	7K	$13.49	$98K	349K
2026-03-02	Cordova Ashley	Former Chief Executive Officer	Tax withholding	7K	$13.67	$99K	440K
2026-03-02	Cordova Ashley	Former Chief Executive Officer	Tax withholding	2K	$13.67	$33K	447K
2026-02-28	Weinberg Uri	Chf Medical and Innovation Ofr	Grant	13K	$0.00	$0	227K
2026-02-28	Leonard Frank X	Chief Executive Officer	Grant	19K	$0.00	$0	357K
2026-02-28	Cordova Ashley	Former Chief Executive Officer	Grant	24K	$0.00	$0	450K
2026-02-28	Ben Arye Barak	General Counsel	Grant	18K	$0.00	$0	192K
2026-02-27	Paravasthu Mukund	Chief Operating Officer	Sell	2K	$13.66	$21K	77K
2026-02-27	Puri Michal Nath	Chief Human Resources Officer	Sell	1K	$13.66	$20K	162K
2026-02-27	Weinberg Uri	Chf Medical and Innovation Ofr	Sell	7K	$13.84	$103K	214K
2026-02-27	Leupin Nicolas	Former Chief Medical Officer	Sell	1K	$13.66	$14K	104K
2026-02-27	Leonard Frank X	Chief Executive Officer	Sell	10K	$13.66	$133K	338K
2026-02-27	Cordova Ashley	Former Chief Executive Officer	Tax withholding	12K	$13.75	$159K	426K
2026-01-11	Paravasthu Mukund	Chief Operating Officer	Tax withholding	2K	$14.35	$31K	78K
2025-11-04	Paravasthu Mukund	Chief Operating Officer	Tax withholding	3K	$12.23	$36K	80K
2025-11-04	Brackmann Christoph	Chief Financial Officer	Tax withholding	7K	$12.23	$86K	134K
2025-11-01	Paravasthu Mukund	Chief Operating Officer	Tax withholding	168	$12.81	$2K	83K
2025-11-01	Leonard Frank X	EVP, Pres., Novocure Oncology	Tax withholding	966	$12.81	$12K	348K
2025-10-31	Puri Michal Nath	Chief Human Resources Officer	Tax withholding	752	$12.82	$10K	164K
2025-09-05	Cordova Ashley	Chief Executive Officer	Buy	82K	$12.22	$997K	438K
2025-07-29	Brackmann Christoph	Chief Financial Officer	Buy	5K	$11.50	$58K	141K
2025-07-29	Brackmann Christoph	Chief Financial Officer	Buy	5K	$11.60	$58K	136K
2025-07-29	Brackmann Christoph	Chief Financial Officer	Buy	10K	$11.63	$116K	131K
2025-06-30	Puri Michal Nath	Chief Human Resources Officer	Grant	833	$15.13	$13K	165K
2025-06-30	Leonard Frank X	EVP, Pres., Novocure Oncology	Grant	833	$15.13	$13K	349K
2025-06-30	Danziger Asaf	Director	Grant	833	$15.13	$13K	416K
2025-06-30	Cordova Ashley	Chief Executive Officer	Grant	833	$15.13	$13K	356K
2025-06-30	Ben Arye Barak	General Counsel	Grant	769	$15.13	$12K	174K
2025-06-04	Leonard Frank X	EVP, Pres., Novocure Oncology	Grant	179K	$0.00	$0	348K
2025-06-04	VERNON W ANTHONY	Director	Grant	11K	$0.00	$0	179K
2025-06-04	Hung David	Director	Grant	11K	$0.00	$0	23K
2025-06-04	Scannell Timothy J	Director	Grant	11K	$0.00	$0	17K
2025-06-04	Ocean Allyson J	Director	Grant	11K	$0.00	$0	14K
2025-06-04	HILLEMAN JERYL L	Director	Grant	11K	$0.00	$0	17K
2025-06-04	Stafford Kristin	Director	Grant	11K	$0.00	$0	14K
2025-06-04	LEUNG GABRIEL	Director	Grant	11K	$0.00	$0	92K
2025-06-03	Hung David	Director	Sell	999	$17.30	$17K	12K
2025-06-03	VERNON W ANTHONY	Director	Sell	999	$17.35	$17K	168K
2025-06-03	Ocean Allyson J	Director	Sell	999	$17.29	$17K	3K
2025-06-03	HILLEMAN JERYL L	Director	Sell	999	$17.26	$17K	6K
2025-06-03	Scannell Timothy J	Director	Sell	999	$17.32	$17K	6K
2025-06-03	Madden Martin J.	Director	Sell	999	$17.19	$17K	19K
2025-06-03	LEUNG GABRIEL	Director	Sell	999	$17.31	$17K	81K
2025-06-03	Stafford Kristin	Director	Sell	999	$17.28	$17K	3K
2025-06-02	Leonard Frank X	EVP, Pres., Novocure Oncology	Sell	2K	$19.01	$36K	168K
2025-06-02	Leonard Frank X	EVP, Pres., Novocure Oncology	Sell	7K	$17.99	$119K	170K
2025-06-02	Leonard Frank X	EVP, Pres., Novocure Oncology	Sell	22K	$17.22	$374K	177K
2025-05-03	Paravasthu Mukund	Chief Operating Officer	Sell	592	$17.91	$11K	84K
2025-03-04	Cordova Ashley	Chief Executive Officer	Grant	151K	$18.19	$2.7M	355K
2025-03-04	Paravasthu Mukund	Chief Operating Officer	Grant	55K	$18.19	$1000K	84K
2025-03-04	Leonard Frank X	EVP, Pres., Novocure Oncology	Grant	55K	$18.19	$1000K	199K
2025-03-04	Weinberg Uri	Chief Innovation Officer	Grant	55K	$18.19	$1000K	221K
2025-03-04	Puri Michal Nath	Chief Human Resources Officer	Grant	55K	$18.19	$1000K	164K
2025-03-04	Ben Arye Barak	General Counsel	Grant	55K	$18.19	$1000K	174K
2025-03-04	Leupin Nicolas	Chief Medical Officer	Grant	55K	$18.19	$1000K	105K
2025-03-04	Brackmann Christoph	Chief Financial Officer	Grant	55K	$18.19	$1000K	121K
2025-03-03	Paravasthu Mukund	Chief Operating Officer	Sell	250	$18.54	$5K	29K
2025-03-03	Cordova Ashley	Chief Executive Officer	Sell	2K	$18.54	$38K	204K
2025-03-03	Leonard Frank X	EVP, Pres., Novocure Oncology	Sell	3K	$18.54	$47K	144K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

12 Form 144 notices on file for NVCR worth $3.4M at the prices reported; 0 in the last 90 days worth $0. Latest: NICOLAS LEUPIN filed on 2026-07-23 to sell 39,088 shares ($609K) from 2026-07-23.

Filed	Seller	Shares	Market value	Of outstanding	Sale from	Broker
2026-07-23	NICOLAS LEUPINOfficer	39K	$609K	0.034%	2026-07-23	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-06-04	FRANCIS LEONARDOfficer	34K	$615K	0.030%	2026-06-04	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-05	MUKUND PARAVASTHUOfficer	43K	$596K	0.038%	2026-03-05	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-04	URI WEINBERGOfficer	6K	$85K	0.006%	2026-03-04	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-04	MUKUND PARAVASTHUOfficer	5K	$72K	0.005%	2026-03-04	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-04	FRANCIS LEONARDOfficer	6K	$75K	0.005%	2026-03-04	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-04	CHRISTOPH BRACKMANNOfficer	6K	$85K	0.006%	2026-03-04	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-03	WILLIAM DOYLEOfficer, Director	72K	$933K	0.063%	2026-03-03	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-02	URI WEINBERGOfficer	3K	$44K	0.003%	2026-03-02	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-02	FRANCIS LEONARDOfficer	7K	$98K	0.006%	2026-03-02	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-02-27	URI WEINBERGOfficer	7K	$103K	0.007%	2026-02-27	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-02-27	FRANCIS LEONARDOfficer	10K	$133K	0.009%	2026-02-27	Morgan Stanley Smith Barney LLC Executive Financial Services

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

7 holders report 5% or more of NVCR in their latest filing, all on Schedule 13G (passive). The largest reported stake is Guy Levy at 9.1% of the class (10,492,391 shares), filed 2026-05-08 for an event on 2026-03-31.

Filed	Form	Holder	Shares	Of class	Event
2026-05-08	13G/Ano. 4	Guy Levyindividual	10.5M	9.1%	2026-03-31
2026-05-08	13G/Ano. 4	Soleus GP, LLCother entity	10.5M	9.1%	2026-03-31
2026-05-08	13G/Ano. 4	Soleus Capital Management, L.P.partnership	10.5M	9.1%	2026-03-31
2026-05-08	13G/Ano. 4	Soleus Capital Group, LLCother entity	10.5M	9.1%	2026-03-31
2026-05-08	13G/Ano. 4	Soleus Capital Master Fund, L.P.non-US institution	10.5M	9.1%	2026-03-31
2026-05-08	13G/Ano. 4	Soleus Capital, LLCother entity	10.5M	9.1%	2026-03-31
2026-04-28	13G	Vanguard Portfolio Managementinvestment adviser	6.3M	5.6%	2026-03-31
2026-03-26	13G/Ano. 8	The Vanguard Groupinvestment adviser	0	0.0%	2026-03-13
2025-11-13	13G/Ano. 1	Capital World Investorsinvestment adviser	2.0M	1.8%	2025-09-30

13F holders

Tracked managers holding NVCR at their latest 13F. JSON

7 of the 30 tracked managers held NVCR at their latest 13F, $80.8M in total at quarter-end prices. Renaissance Technologies is the largest at $29.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Renaissance Technologies	2026-06-30	2.0M	$29.6M	0.04%	+400K
AQR Capital Management	2026-06-30	1.1M	$16.7M	0.01%	+827K
D. E. Shaw & Co.	2026-06-30	1.0M	$15.5M	0.01%	+375K
Point72 Asset Management	2026-06-30	803K	$12.2M	0.01%	-558K
Millennium Management	2026-06-30	278K	$4.2M	0.00%	+187K
Citadel Advisors	2026-06-30	157K	$2.4M	0.00%	+71K
Two Sigma Investments	2026-06-30	21K	$321K	0.00%	-24K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q3 FY 2027 (quarter ended 2026-09-30) NovoCure reported revenue of $193.4M, up 15.7% from the same quarter a year earlier, and net loss of $10.4M (-0.09 diluted EPS). In FY 2025 it generated -$26.4M of operating cash flow.

Cash: $96.7M
Equity: $350.6M
Total assets: $828.7M
Shares outstanding: 116,915,959

Quarterly, last 8 quarters

Quarter	Period end	Revenue	Net income	Margin	Diluted EPS
Q3 FY 2027	2026-09-30	$193.4M	-$10.4M	-5.4%	-0.09
Q2 FY 2027	2026-06-30	$183.6M	-$15.7M	-8.5%	-0.13
Q1 FY 2027	2026-03-31	$174.1M	-$71.1M	-40.9%	-0.62
Q3 FY 2026	2025-09-30	$167.2M	-$37.3M	-22.3%	-0.33
Q2 FY 2026	2025-06-30	$158.8M	-$40.1M	-25.3%	-0.36
Q1 FY 2026	2025-03-31	$155.0M	-$34.3M	-22.1%	-0.31
Q4 FY 2025derived	2024-12-31	$161.3M	-$65.9M	-40.9%	n/a
Q3 FY 2025	2024-09-30	$155.1M	-$30.6M	-19.7%	-0.28

Fiscal years, with buybacks and dividends

Fiscal year	Ends	Revenue	Net income	Operating cash flow	Capex	Buybacks	Dividends
FY 2025	2024-12-31	$605.2M	-$168.6M	-$26.4M	$42.9M	n/a	n/a
FY 2024	2023-12-31	$509.3M	-$207.0M	-$73.3M	$27.1M	n/a	n/a
FY 2023	2022-12-31	$537.8M	-$92.5M	$30.8M	$21.4M	n/a	n/a
FY 2022	2021-12-31	$535.0M	-$58.4M	$82.8M	$24.2M	n/a	n/a
FY 2021	2020-12-31	$494.4M	$19.8M	$99.1M	$15.0M	n/a	n/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30; shares outstanding as of 2026-10-23 from the cover page.

What this page is

NovoCure in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows NovoCure (NVCR), SEC CIK 1645113, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
Planned sales: SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-23.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-08.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials: SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-29.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-30.JSON and CSV
Company record: EDGAR filing index for CIK 1645113Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as surgical & medical instruments & apparatus

Other company pages

Datasets

Frequently Asked Questions

How much of NVCR is sold short?

12,823,054 shares were held short at the 2026-10-15 settlement, 7.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is NVCR's daily short volume?

On 2026-11-02, 219,408 of the 562,337 NVCR shares reported to FINRA were sold short, 39.0% of the day's reported volume. Short volume is a flow for one day, not a position.

Does NVCR have fails to deliver?

The SEC's latest file shows 111 NVCR shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.

Are NVCR insiders buying or selling?

No open-market insider trades were reported for NVCR in the last 90 days. The most recent filings are listed below. Latest filing: Puri Michal Nath (Chief Human Resources Officer) on 2026-06-30.

Have NVCR insiders filed to sell?

12 Form 144 notices on file for NVCR worth $3.4M at the prices reported; 0 in the last 90 days worth $0. Latest: NICOLAS LEUPIN filed on 2026-07-23 to sell 39,088 shares ($609K) from 2026-07-23.

Who owns 5% or more of NVCR?

What did NVCR report last quarter?

Which tracked 13F managers own NVCR?

7 of the 30 tracked 13F managers held NVCR shares at their latest filing, $80.8M in all. The largest: Renaissance Technologies (2.0M shares, $29.6M), Cliff Asness's AQR Capital Management (1.1M shares, $16.7M), D. E. Shaw & Co. (1.0M shares, $15.5M), Steve Cohen's Point72 Asset Management (803K shares, $12.2M), Izzy Englander's Millennium Management (278K shares, $4.2M), Ken Griffin's Citadel Advisors (157K shares, $2.4M). The table above lists all 7.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.